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Treatment Planning 
Target Volumes:  
- Computed tomography simulation (CT-sim), and 
magnetic resonance imaging (MRI) are used to 
set up treatment plans
- Primary clinical target volume (CTV-P) could 
include the whole prostate including seminal 
vesicle, and are only included if believed to be 
cancerous
- If seminal vesicle aren’t involved the CTV-P will 
include typically 2cm of the seminal vesicles
(Telkhade et al., 2021 p. 173) 
- Planning Target Volumes (PTVs) are 3 to 5mm, 
and in order to avoid the rectum the restrictions 
tend to be stricter posteriorly (Kothari et al,, 2018, p. 8)
- PTVs can be broken down into high dose (HD-
PTV) and low dose (LD-PTVs)
Treatment Plan: Contouring of PTVs
(Xia, Godley, Shah, Videtic, & Suh, 2018,  p. 176)
Organs at Risk (OARs):
- Healthy organs and tissues that can be damaged 




- Penile Bulb 
- Femoral Head 
- Colon
(Xia, et al., 2018, p. 177)
Treatment
Procedures: 
- Patient should be simulated with full bladder 
and empty rectum every treatment
- The bladder and rectum restrictions help push 
the bowel out the field and reduce radiation to 
the bladder (Xia, et al., 2018, p. 175)
- A rectal balloon can be placed to immobilized 
the rectum which allows for better separation 
between anterior wall & prostate (Xia, et al., 2018, p. 
172)
- SpaceOAR hydrogel can also be used to move 
the rectum farther away from the prostate (Kothari 
et al., 2018, p. 8)
Motion monitoring:
- Fiducial markers can be placed in order to track 
movement using triggered imaging. When 
movement is out of allowed parameters, 
treatment will automatically stop until mark is 
placed back into the right position (Xia ,et al., 2018, 
p.172)
- Real time motion monitoring such as Calypso, 
and RayPilot are used to continuously monitor 
the prostate, which allows for beam-gating and 
patient realignment to ensure proper areas are 
being treated
- The use of continuous motion monitoring allows 
for lower PTVs, and less exposure to OARs at 
risk                                                                   
(Vanhanen, Poulsen, & Kapen, 2020 p. 58)
Dose:
- Commonly around 35 to 36.25 Gray (Gy).
- 40 Gy is also an acceptable dose for treatment
- Treatment is typically, around 5 fractions, 1 per 
day                                          (Kothari et al., 2018, p. 5) 
Treatment Plan: Isodose lines 
(Xia, et al., 2018, p. 180)
Why SBRT for Treatment?
- SBRT is noninvasive compared to other 
treatment options such as surgery and 
brachytherapy
- Prostate cancer has a low alpha/beta ratio 
making it very sensitive to high doses of 
radiation (Vanhanen, Poulsen, & Kapen, 2020 p. 58)
- Low rates of serve toxic events and good 
biochemical control
- A study done on 2142 men with low-risk and 
intermediate-risk prostate cancer, showed 
SBRT treatment had good outcomes, low rate 
of severe toxic events, and high rates had 
biochemical control (Kishan et al., 2019, p. 1)
- Biochemical control rates were “less than 10% 
for low-risk and favorable intermediate-risk 
disease and just 15% for unfavorable 
intermediate-risk disease” (Kishan et al., 2019, p. 8)
Biochemical Recurrence 
(Kishan et al., 2019, p. 6)
- Due to higher dose, there are less treatments 
making SBRT more time and cost efficient (Kothari 
et al., 2018, p. 3)
- Time efficiency leads to better satisfied 
patients, because it shortens length of 
treatment, a common complaint among patients 
(Kothari et al., 2018, p. 3)
- SBRT is a safe and efficient way to treat pelvic-
node in node-positive prostate cancer according 
to a study done on 60 lymph node positive 
prostate cancer patients (Telkhade et al., 2021 p. 179)
Conclusion
- Stereotactic body radiotherapy is an acceptable 
treatment for low-risk, intermediate-risk, and 
lymph node positive prostate cancer
- Continuous motion monitoring  of the prostate is 
crucial to lower exposure to organs at risk, and 
to lower planning target volumes
Prostate Cancer
- Occurs when the cells grow out of control in the 
prostate gland
- Most prostate cancers are slow to grow and 
spread
- Develops in older men, average age of  
diagnosis is 66
- Second most common cancer in American men
- 1 in 8 men have prostate cancer
(American Cancer Society, 2021, para. 2-4)
(American Cancer Society, 2019, para. 1-2)
Types of Prostate Cancer 
- Adenocarcinoma is the most common type
- Other types are small cell carcinomas, 
neuroendocrine tumors, sarcomas, but these 
are rare and unlikely
(American Cancer Society, 2019, para. 5) 
` (American Cancer Society, 2021, para. 3)  
Treatment Options
- Radical prostatectomy 
- External beam radiotherapy 
- Brachytherapy 
- Stereotactic body radiotherapy  (Kothari et al, 2018, p. 2) 
Stereotactic Body Radiotherapy (SBRT)
- "administers very high doses of radiation, using 
several beams of various intensities aimed at 
different angles to precisely target the tumor” 
(MD Anderson Cancer Center, n.d., para. 1)
- Treatment is typically either one or five doses 
once a day but can be different based on type 
and location of the cancer (MD Anderson Cancer Center, 
n.d., para. 3)
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